Ignite Creation Date:
2024-05-06 @ 3:51 PM
Last Modification Date:
2024-10-26 @ 1:58 PM
Study NCT ID:
NCT04784546
Status:
COMPLETED
Last Update Posted:
2021-10-12
First Post:
2021-03-01
Brief Title:
Evaluation of Muscle Strength Functional Independence Myalgia Fatigue and Dyspnea in COVID-19 Infection
Sponsor:
Gazi University
Organization:
Gazi University
Study Overview
Official Title:
Evaluation of Muscle Strength Functional Independence Myalgia Severity Physical Fatigue and Dyspnea in Patients With COVID-19 Infection
Status:
COMPLETED
Status Verified Date:
2021-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Coronavirus disease 2019 COVID-19 is a serious acute infectious disease caused by Serious Acute Respiratory Syndrome Coronavirus 2 SARS-CoV-2 COVID-19 can manifest itself in a wide variety of clinical scenarios Asymptomatic disease mild flu findings pneumonia accompanied by acute respiratory failure acute respiratory distress syndrome ARDS requiring hospitalization in the intensive care unit and death are possible clinical consequences
Myalgia fatigue and muscle weakness are reported regardless of the severity of the clinical presentation of COVID-19 Data on the prevalence and severity of muscle disorders and weakness during hospitalization and discharge due to COVID-19 disease are limited
The aim of this study is to evaluate muscle strength functional independence myalgia severity physical fatigue and dyspnea in hospitalized COVID-19 patients
Myalgia fatigue and muscle weakness are reported regardless of the severity of the clinical presentation of COVID-19 Data on the prevalence and severity of muscle disorders and weakness during hospitalization and discharge due to COVID-19 disease are limited
The aim of this study is to evaluate muscle strength functional independence myalgia severity physical fatigue and dyspnea in hospitalized COVID-19 patients
Detailed Description:
Coronavirus disease 2019 COVID-19 is a serious acute infectious disease caused by Serious Acute Respiratory Syndrome Coronavirus 2 SARS-CoV-2 On March 11 2020 the World Health Organization declared a pandemic due to COVID-19 disease transmitted from person to person Positive COVID-19 patients are classified as asymptomatic mild moderate severe and critical Asymptomatic patients have no clinical symptoms mild cases present with acute symptoms of respiratory tract infection and gastrointestinal complaints Moderate patients experience pneumonia they dont have clinically aberrant hypoxemia but they have positive findings on chest computerized tomography CT scans Severe patients present with pneumonia they have hypoxemia and CT lesions while critical patients present with acute respiratory distress syndrome ARDS and shock encephalopathy myocardial injury coagulation dysfunction heart failure acute kidney injury may accompany ARDS
Myalgia fatigue and muscle weakness are reported regardless of the severity of the clinical presentation of COVID-19 disease Data on the prevalence and severity of muscle disorders and weakness during hospitalization and discharge due to COVID-19 disease are limited
Changes associated with critical disease myopathy triggered by the virus are reported in COVID-19 survivors
In addition immune-induced focal myofibril atrophy and necrosis have been documented in post-mortem examinations of patients with severe acute respiratory syndrome SARS An increase in the risk of acute sarcopenia and muscle weakness has been reported in survivors of COVID-19 Possible mechanisms of sarcopenia in COVID-19 disease are suppression of muscle protein synthesis due to systemic inflammation and increased cytokine response prolonged bed rest especially in intensive care patients prolonged use of muscle relaxants to maintain the prone position increased need for nutrients due to the catabolic state inadequate nutrition due to decreased appetite and induction of muscle loss by dexamethasone used in COVID-19 treatment
The aim of this study is to evaluate muscle strength functional independence myalgia severity physical fatigue and dyspnea in hospitalized COVID-19 patients and to investigate whether these variables differ between the mild moderate and severe groups according to the severity of the disease The secondary aim of the study is to investigate the relationship between muscle strength and prognostic markers of COVID-19 disease lymphocyte count D-dimer c-reactive protein ferritin
Myalgia fatigue and muscle weakness are reported regardless of the severity of the clinical presentation of COVID-19 disease Data on the prevalence and severity of muscle disorders and weakness during hospitalization and discharge due to COVID-19 disease are limited
Changes associated with critical disease myopathy triggered by the virus are reported in COVID-19 survivors
In addition immune-induced focal myofibril atrophy and necrosis have been documented in post-mortem examinations of patients with severe acute respiratory syndrome SARS An increase in the risk of acute sarcopenia and muscle weakness has been reported in survivors of COVID-19 Possible mechanisms of sarcopenia in COVID-19 disease are suppression of muscle protein synthesis due to systemic inflammation and increased cytokine response prolonged bed rest especially in intensive care patients prolonged use of muscle relaxants to maintain the prone position increased need for nutrients due to the catabolic state inadequate nutrition due to decreased appetite and induction of muscle loss by dexamethasone used in COVID-19 treatment
The aim of this study is to evaluate muscle strength functional independence myalgia severity physical fatigue and dyspnea in hospitalized COVID-19 patients and to investigate whether these variables differ between the mild moderate and severe groups according to the severity of the disease The secondary aim of the study is to investigate the relationship between muscle strength and prognostic markers of COVID-19 disease lymphocyte count D-dimer c-reactive protein ferritin
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None